Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy.

However, when indirect comparisons were performed, the magnitude of this difference was minor of those reported previously, and did not reach statistical significance.

also in 111,027 other papers